246 related articles for article (PubMed ID: 37432690)
1. Baseline Features and Reasons for Nonparticipation in the Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM) Study, a Colorectal Cancer Screening Trial.
Robertson DJ; Dominitz JA; Beed A; Boardman KD; Del Curto BJ; Guarino PD; Imperiale TF; LaCasse A; Larson MF; Gupta S; Lieberman D; Planeta B; Shaukat A; Sultan S; Menees SB; Saini SD; Schoenfeld P; Goebel S; von Rosenvinge EC; Baffy G; Halasz I; Pedrosa MC; Kahng LS; Cassim R; Greer KB; Kinnard MF; Bhatt DB; Dunbar KB; Harford WV; Mengshol JA; Olson JE; Patel SG; Antaki F; Fisher DA; Sullivan BA; Lenza C; Prajapati DN; Wong H; Beyth R; Lieb JG; Manlolo J; Ona FV; Cole RA; Khalaf N; Kahi CJ; Kohli DR; Rai T; Sharma P; Anastasiou J; Hagedorn C; Fernando RS; Jackson CS; Jamal MM; Lee RH; Merchant F; May FP; Pisegna JR; Omer E; Parajuli D; Said A; Nguyen TD; Tombazzi CR; Feldman PA; Jacob L; Koppelman RN; Lehenbauer KP; Desai DS; Madhoun MF; Tierney WM; Ho MQ; Hockman HJ; Lopez C; Carter Paulson E; Tobi M; Pinillos HL; Young M; Ho NC; Mascarenhas R; Promrat K; Mutha PR; Pandak WM; Shah T; Schubert M; Pancotto FS; Gawron AJ; Underwood AE; Ho SB; Magno-Pagatzaurtundua P; Toro DH; Beymer CH; Kaz AM; Elwing J; Gill JA; Goldsmith SF; Yao MD; Protiva P; Pohl H; Kyriakides T;
JAMA Netw Open; 2023 Jul; 6(7):e2321730. PubMed ID: 37432690
[TBL] [Abstract][Full Text] [Related]
2. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
4. Colonoscopy vs. Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM): Rationale for Study Design.
Dominitz JA; Robertson DJ; Ahnen DJ; Allison JE; Antonelli M; Boardman KD; Ciarleglio M; Del Curto BJ; Huang GD; Imperiale TF; Larson MF; Lieberman D; O'Connor T; O'Leary TJ; Peduzzi P; Provenzale D; Shaukat A; Sultan S; Voorhees A; Wallace R; Guarino PD
Am J Gastroenterol; 2017 Nov; 112(11):1736-1746. PubMed ID: 29016565
[TBL] [Abstract][Full Text] [Related]
5. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies.
Inadomi JM; Vijan S; Janz NK; Fagerlin A; Thomas JP; Lin YV; Muñoz R; Lau C; Somsouk M; El-Nachef N; Hayward RA
Arch Intern Med; 2012 Apr; 172(7):575-82. PubMed ID: 22493463
[TBL] [Abstract][Full Text] [Related]
6. Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.
Halm EA; Beaber EF; McLerran D; Chubak J; Corley DA; Rutter CM; Doubeni CA; Haas JS; Balasubramanian BA
J Gen Intern Med; 2016 Oct; 31(10):1190-7. PubMed ID: 27279097
[TBL] [Abstract][Full Text] [Related]
7. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
[TBL] [Abstract][Full Text] [Related]
8. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening.
DeBourcy AC; Lichtenberger S; Felton S; Butterfield KT; Ahnen DJ; Denberg TD
J Gen Intern Med; 2008 Feb; 23(2):169-74. PubMed ID: 18157581
[TBL] [Abstract][Full Text] [Related]
9. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of screening using annual fecal immunochemical test alone versus combined with one-time colonoscopy in reducing colorectal cancer mortality: the Akita Japan population-based colonoscopy screening trial (Akita pop-colon trial).
Saito H; Kudo SE; Takahashi N; Yamamoto S; Kodama K; Nagata K; Mizota Y; Ishida F; Ohashi Y
Int J Colorectal Dis; 2020 May; 35(5):933-939. PubMed ID: 32034490
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the OC Sensor
Vitellius C; Laly M; Banaszuk AS; Deherce I; Cornet N; Bertrais S; Saulnier P; Caroli-Bosc FX
Eur J Epidemiol; 2019 Feb; 34(2):163-172. PubMed ID: 30536183
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.
Gupta S; Halm EA; Rockey DC; Hammons M; Koch M; Carter E; Valdez L; Tong L; Ahn C; Kashner M; Argenbright K; Tiro J; Geng Z; Pruitt S; Skinner CS
JAMA Intern Med; 2013 Oct; 173(18):1725-32. PubMed ID: 23921906
[TBL] [Abstract][Full Text] [Related]
13. Time to Colonoscopy After Abnormal Stool-Based Screening and Risk for Colorectal Cancer Incidence and Mortality.
San Miguel Y; Demb J; Martinez ME; Gupta S; May FP
Gastroenterology; 2021 May; 160(6):1997-2005.e3. PubMed ID: 33545140
[TBL] [Abstract][Full Text] [Related]
14. Multitarget Stool RNA Test for Colorectal Cancer Screening.
Barnell EK; Wurtzler EM; La Rocca J; Fitzgerald T; Petrone J; Hao Y; Kang Y; Holmes FL; Lieberman DA
JAMA; 2023 Nov; 330(18):1760-1768. PubMed ID: 37870871
[TBL] [Abstract][Full Text] [Related]
15. Association of Race and Socioeconomic Status With Colorectal Cancer Screening, Colorectal Cancer Risk, and Mortality in Southern US Adults.
Warren Andersen S; Blot WJ; Lipworth L; Steinwandel M; Murff HJ; Zheng W
JAMA Netw Open; 2019 Dec; 2(12):e1917995. PubMed ID: 31860105
[TBL] [Abstract][Full Text] [Related]
16. Utilization of a Colorectal Cancer Screening Test Among Individuals With Average Risk.
Fisher DA; Princic N; Miller-Wilson LA; Wilson K; Fendrick AM; Limburg P
JAMA Netw Open; 2021 Sep; 4(9):e2122269. PubMed ID: 34473259
[TBL] [Abstract][Full Text] [Related]
17. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study).
González-López N; Quintero E; Gimeno-Garcia AZ; Bujanda L; Banales J; Cubiella J; Salve-Bouzo M; Herrero-Rivas JM; Cid-Delgado E; Alvarez-Sanchez V; Ledo-Rodríguez A; de-Castro-Parga ML; Fernández-Poceiro R; Sanromán-Álvarez L; Santiago-Garcia J; Herreros-de-Tejada A; Ocaña-Bombardo T; Balaguer F; Rodríguez-Soler M; Jover R; Ponce M; Alvarez-Urturi C; Bessa X; Roncales MP; Sopeña F; Lanas A; Nicolás-Pérez D; Adrián-de-Ganzo Z; Carrillo-Palau M; González-Dávila E;
PLoS Med; 2023 Oct; 20(10):e1004298. PubMed ID: 37874831
[TBL] [Abstract][Full Text] [Related]
18. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
[TBL] [Abstract][Full Text] [Related]
19. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
